| Genotyping the future: scientists' expectations about race/ ethnicity after BiDil. | |
| | |
MedLine Citation:
|
PMID: 18840237 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The ongoing debate about the FDA approval of BiDil in 2005 demonstrates how the first racially/ethnically licensed drug is entangled in both Utopian and dystopian future visions about the continued saliency of race/ethnicity in science and medicine. Drawing on the sociology of expectations, this paper analyzes how scientists in the field of pharmacogenetics are constructing certain visions of the future with respect to the use of social categories of race/ethnicity and the impact of high-throughput genotyping technologies that promise to transform scientific practices. |
| | |
Authors:
|
Richard Tutton; Andrew Smart; Paul A Martin; Richard Ashcroft; George T H Ellison |
Related Documents
:
|
8249057 - Royal society of tropical medicine and hygiene meeting at manson house, london, 10 dece... 9171837 - The place of "the tropics' in western medical ideas since 1750. 21079057 - Uncertainty in the perioperative management of high-risk cutaneous squamous cell carcin... 21824147 - Antimicrobial usage in dogs and cats in first opinion veterinary practices in the uk. 22556777 - Practice of pancakarma in western countries - a german experience. 11881857 - Non-interventional and interventional transvaginal ultrasound in present day infertilit... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics Volume: 36 ISSN: 1073-1105 ISO Abbreviation: J Law Med Ethics Publication Date: 2008 |
Date Detail:
|
Created Date: 2008-10-08 Completed Date: 2008-11-25 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9315583 Medline TA: J Law Med Ethics Country: United States |
Other Details:
|
Languages: eng Pagination: 464-70 Citation Subset: T |
Affiliation:
|
ESRC Centre for Economic and Social Aspects of Genomics (CESA-Gen), Institute for Advanced Studies, Lancaster University, Lancaster, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Continental Population Groups
/
genetics* Drug Combinations Genetics, Population Heart Failure / drug therapy, ethnology Humans Hydralazine / therapeutic use* Isosorbide Dinitrate / therapeutic use* Pharmacogenetics* Sex Vasodilator Agents / therapeutic use* |
| Grant Support | |
ID/Acronym/Agency:
|
073524/Z/03/Z/AW/HH//Wellcome Trust |
| Chemical | |
Reg. No./Substance:
|
0/Drug Combinations; 0/Vasodilator Agents; 0/isosorbide-hydralazine combination; 86-54-4/Hydralazine; 87-33-2/Isosorbide Dinitrate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Fixed-dose isosorbide dinitrate-hydralazine: race-based cardiovascular medicine benefit or mirage?
Next Document: "Special treatment": BiDil, Tuskegee, and the logic of race.